for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boiron SA

BOIR.PA

Latest Trade

33.60EUR

Change

0.05(+0.15%)

Volume

7,596

Today's Range

33.20

 - 

34.00

52 Week Range

32.10

 - 

59.40

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
33.55
Open
33.50
Volume
7,596
3M AVG Volume
0.30
Today's High
34.00
Today's Low
33.20
52 Week High
59.40
52 Week Low
32.10
Shares Out (MIL)
17.51
Market Cap (MIL)
589.32
Forward P/E
15.98
Dividend (Yield %)
4.77

Latest Developments

More

Boiron H1 Net Result Turns To Loss Of 0.4 Million Euros

Boiron H1 Sales Drops To 256.7 Million Euros

Boiron Sees 60% Of Its Activity Directly Affected By Change Of Reimbursement Rate Of Homeopathic Medicines

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boiron SA

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

Industry

Biotechnology & Drugs

Contact Info

2 avenue de l ouest Lyonnais

+33.4.78456100

http://www.boiron.fr/

Executive Leadership

Thierry Boiron

Chairman of the Board of Directors, Director

Valerie Poinsot

Chief Executive Officer, Director

Jean-Christophe Michel Bayssat

Deputy Chief Executive Officer, Chief Pharmacist, Pharmaceutical Development Director

Jacky Abecassis

Non-Executive Director

Michele Boiron

Non-Executive Director

Key Stats

4.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.6K

2017

0.6K

2018

0.6K

2019(E)

0.6K
EPS (EUR)

2016

4.220

2017

4.250

2018

3.230

2019(E)

2.100
Price To Earnings (TTM)
16.58
Price To Sales (TTM)
1.02
Price To Book (MRQ)
1.29
Price To Cash Flow (TTM)
8.21
Total Debt To Equity (MRQ)
3.28
LT Debt To Equity (MRQ)
2.09
Return on Investment (TTM)
6.12
Return on Equity (TTM)
4.94

Latest News

BRIEF-Boiron: HAS Maintains Unfavorable Opinion Regarding Reimbursement Of Homeopathic Medicines

* HAUTE AUTORITE DE SANTE (HAS) HAS MAINTAINED ITS UNFAVORABLE OPINION REGARDING THE REIMBURSEMENT OF HOMEOPATHIC MEDICINES

BRIEF-Boiron Q1 Revenue Broadly Stable At 159.4 Million Euros

* TURNOVER IN Q1 OF 2018 IS ALMOST STABLE (-0.5%) IN COMPARISON TO Q1 OF 2017

BRIEF-Boiron FY Operating Income Down At 125.0 Million Euros

* FY OPERATING INCOME EUR 125.0 MILLION VERSUS EUR 129.7 MILLION YEAR AGO

BRIEF-Boiron FY Revenue up at 617.5 Million Euros

* FY REVENUE EUR 617.5 MILLION VERSUS EUR 614.5 MILLION YEAR AGO

BRIEF-Boiron Q3 revenue increases to 163.9 million euros

* Q3 REVENUE EUR 163.9 MILLION VERSUS EUR 159.4 MILLION YEAR AGO

BRIEF-Boiron H1 operating result down 5.4 pct to 41.1 million euros

* H1 OPERATING RESULT EUR 41.1 MILLION VERSUS EUR 43.4 MILLION YEAR AGO

BRIEF-Boiron says Canadian Supreme Court allows class action to proceed

* SAID ON THURSDAY THE SUPREME COURT IN CANADA REJECTED THE APPEAL OF OUR CANADIAN SUBSIDIARY AGAINST THE JUDGMENT DATED OCTOBER 26, 2016 OF THE QUEBEC COURT OF APPEAL

BRIEF-Boiron Q1 revenue up at 160.3 mln euros

* Q1 revenue 160.3 million euros ($172.1 million) versus 154.1 million euros year ago

BRIEF-Boiron FY net income group share rises to 77.7 million euros

* FY revenue 614.5 million euros ($653.52 million) versus 607.8 million euros year ago

BRIEF-Boiron announces acquisition of Laboratoire Ferrier

* Laboratoires Boiron and Laboratoires Arkopharma signed an agreement for the takeover on 1st of March 2017 by Boiron of Laboratoire Ferrier, a subsidiary of Arkopharma

BRIEF-Boiron FY revenue up at 614.5 million euros

* FY revenue 614.5 million euros ($655.73 million) versus 607.8 million euros year ago

BRIEF-Boiron H1 operating profit up 14.7 mln at 43.4 mln euros

* H1 sales is 284.3 million euros ($320.1 million) versus 275.6 million euros a year ago

BRIEF-Boiron H1 net income group share rises 23.3 pct

* Reports H1 net income group share of 26.5 million euros versus 21.5 million euros a year ago See also: Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up